Menu
Curie Logo
Donate
  • Home

Clinical trials - page 2

Essais cliniques
Search for a clinical trial
Filter

195 result(s)

  • ENT/Head and Neck Cancers
    Paris, Saint-Cloud
    NIVOPOST-OP / GORTEC 2018-01
    A Trial Evaluating the Addition of Nivolumab to Cisplatin-RT for Treatment of Cancers of the Head and Neck (NIVOPOSTOP)

    CHRISTOPHE LE TOURNEAU, LAURENCE BOZEC

  • Lung cancer
    Paris, Saint-Cloud
    PACT-01
    Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer.

    CATHERINE DANIEL, MARIE ANGE MASSIANI

  • Paris
    PLUME
    A phase II, monocentric, single arm trial;evaluating the efficacy and safety of;Pembrolizumab in combination with Lenvatinib;in metastatic Uveal MElanoma patients

    MANUEL RODRIGUES

  • Prostate cancer
    Paris
    PRESTO (GETUG-AFU 36)
    Prostate-cancer treatment using stereotactic radiotherapy for oligometastases;ablation in hormone-sensitive patients À a GETUG-AFU phase III randomized controlled trial

    GILLES CREHANGE

  • Lung cancer
    Paris, Saint-Cloud
    REAL MOOV LUNG
    Real Life Prospective Multicentric Study Evaluating the Clinical and Organisational Impact of Moovcare® Lung Connected Medical Device in Lung Cancer Patients : REAL-MOOV-LUNG

    NICOLAS GIRARD

  • Lung cancer
    Paris
    RMC-LUNG-101
    Phase 1b/2 Open-Label, Multicenter Study of RMC-6291 in Combination with Pembrolizumab with or without Chemotherapy, in Patients with KRASG12C-Mutated Solid Tumors

    PAULINE DU RUSQUEC

  • Breast cancer
    Paris, Saint-Cloud
    ROMANCE (RAD05-UC-0107/1803)
    Prospective study of omission of whole-breast radiotherapy following breast-conserving surgery in patients with very low risk ductal carcinoma in situ of the breast

  • Childhood and adolescent cancers
    Paris
    SIOP EPENDYMOMA II
    An International Clinical Program for the Diagnosis and Treatment of Children, Adolescents and Young Adults With Ependymoma

    FRANCOIS DOZ

  • Breast cancer
    Paris, Saint-Cloud
    SKYLINE
    Tiragolumab, atezolizumab and chemotherapy in triple negative breast cancer:;A phase II trial.

    FRANCOIS-CLEMENT BIDARD

  • Lung cancer
    Paris
    TAS6417-301
    Randomized, Controlled, Open-label, Phase 3, Global Multi-;Center Trial to Assess the Efficacy and Safety of Zipalertinib;plus Chemotherapy versus Chemotherapy alone, in Patients;with Previously Untreated, Locally Advanced or Metastatic;Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with;Epidermal Growth Factor Receptor (EGFR) Exon 20;Insertion (ex20ins) Mutations.

    NICOLAS GIRARD

  • Prostate cancer
    Paris, Saint-Cloud
    TEMPOS (GETUG P14)
    Erectile Dysfunction in Good Prognosis Prostate Cancer: a Phase III Medico-economic Study Comparing Brachytherapy to Stereotactic Body Radiotherapy

    GILLES CREHANGE

  • Sarcomas
    Paris
    TRUST
    Bintrafusp Alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced Sarcoma (TRUST)

    CLEMENT BONNET

  • Paris
    CP-START 001
    Open-label, First-in-Human, Phase 1/2 Study with Dose Escalation and Expansion of STAR0602, a Bifunctional Antibody Fusion Targeting Selective T Cell Receptors (TCR), in Patients with Unresectable, Locally Advanced, or Metastatic Antigen-Rich Solid Tumors (START-001).

    CHRISTOPHE LE TOURNEAU

  • Paris, Saint-Cloud
    POP-ART
    A Phase I Study on Tuvusertib (oral ATR inhibitor) in Combination with PLX038 (Topo1 inhibitor) with dose expansion cohorts in patients;with advanced solid tumors.

    FRANCOIS-CLEMENT BIDARD

  • Breast cancer
    Paris, Saint-Cloud
    CAMBRIA-2
    CAMBRIA-2: A Phase III, Randomised, Open-label Study to Evaluate the Efficacy and Safety of Camizestrant (AZD9833), a Next Generation Oral Selective Estrogen Receptor Degrader (ngSERD), Compared with Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment in Patients with Estrogen Receptor-positive, HER2-negative Early Breast Cancer at Medium to High or High Risk of Recurrence, Who Have Completed Definitive Locoregional Therapy and Have No Evidence of Disease.

    PAUL-HENRI COTTU, FRANCOIS-CLEMENT BIDARD

  • Sarcomas
    Paris
    TANGENT (SNX-301-020)
    A Phase III, Multicentre, Randomised, Double-Blind Study to Assess the Safety and Efficacy of Emactuzumab vs. Placebo in Subjects with Tenosynovial Giant Cell Tumour.

    SOPHIE PIPERNO-NEUMANN

  • Lung cancer
    Paris
    R2810-ONC-2268
    A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE;CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS;CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE;PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE;NON-SMALL CELL LUNG CANCER;SUBPROTOCOL 1: REGN7075

    NICOLAS GIRARD

  • Paris
    DF6215-001
    A Phase 1/1b, First-In-Human, Multi-Part, Open-Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of DF6215 in Patients with Advanced (Unresectable, Recurrent, or Metastatic) Solid Tumors

    EMANUELA ROMANO

  • Lung cancer
    Paris
    MK-2870-004
    A Randomized, Open-label, Phase 3 Study of MK-2870 vs Chemotherapy;(Docetaxel or Pemetrexed) in Previously Treated Advanced or Metastatic Nonsquamous;Non-small Cell Lung Cancer (NSCLC) with EGFR Mutations or Other Genomic Alterations.

    CATHERINE DANIEL

  • Paris
    EUonQoL
    Quality of Life in Oncology: measuring what matters for cancer patients and survivors in Europe · Developing the toolkit: Patient preferences and priorities for quality of life domains across the cancer care continuum.

  • Lung cancer
    Paris
    HARMONi-3
    A randomized, controlled, multiregional Phase 3 study of ivonescimab combined with chemotherapy versus pembrolizumab combined with chemotherapy for the first-line treatment of metastatic squamous non-small cell lung cancer.

    PAULINE DU RUSQUEC

  • Paris, Saint-Cloud
    PALLU
    A randomized comparative prospective multicenter study of the efficacy of a systematic referral to palliative care of patients who need for palliative care during an unscheduled visit in comprehensive anticancer centers.

    CAROLE BOULEUC-PARROT

  • Paris
    MK3475-522 (Keynote-522)
    A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC)

    MARIE PAULE SABLIN

  • Childhood and adolescent cancers
    Paris
    I3Y-MC-JPEH
    A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy

    ISABELLE AERTS GAJDOS

  • Paris
    GSK 219451 - POPSTAR
    Phase 1/2 Dose Determination and Dose Expansion Study of Cobolimab in Combination with Dostarlimab in Pediatric and Young Adult Participants with Newly Diagnosed and Relapsed/Refractory Tumors (POPSTAR).

    AMAURY LERUSTE

  • Paris, Saint-Cloud
    REVCCI
    Use of Virtual Reality Mask or Music Therapy for Analgesia and Anxiolytic Purpose When Totally Implanted Venous Access Device (IVAD) for Chemotherapy Under Local Anesthesia

    ABDELMALEK GHIMOUZ

  • Paris, Saint-Cloud
    ESTROTIMP
    Impact of 18F-FES PET on the Therapeutic Treatment of Patients With Metastatic Breast Cancer (ESTROTIMP)

    AUDREY BELLESOEUR

  • Cancers gynécologiques
    Paris, Saint-Cloud
    COLIBRI- 2
    Phase·Ib/II, multicenter, open-label study evaluating BDC-1001, a HER2-targeted TLR7/8 agonist antibody-drug conjugate, as monotherapy and in combination with nivolumab in advanced HER2-expressing solid tumors.

    HELENE SALAUN

  • Colorectal cancer
    Saint-Cloud
    ADAGE - Prodige 34
    Randomised Phase III Study Evaluating Adjuvant Chemotherapy After Resection of Stage III Colonic Adenocarcinoma in Patients of 70 and Over.

  • Cancers gynécologiques
    Saint-Cloud
    AFTERGYN
    Optimize the Support of Patients in Pelvic Onco-gynecology Through Adapted Support Care in the Post-cancer Period. AFTERGYN Pilot Phase (AFTERGYN)

    DIANA BELLO ROUFAI

<
1 2...7
>